Severe Allergic Reaction (Anaphylactic Reaction)
Patients who are on treatment with Cefuroxime AXetil and allergic to beta-lactam antibacterials are at an increased risk when using this medicine. Such patients are more likely to have an increased risk of fatal allergic reactions. This medicine is not recommended for use in patients who are allergic to beta-lactam antibacterials. Discontinue the use of Cefuroxime AXetil, if any allergic reaction occurs.
Diarrhea due to Bacterial Infection
Patients on treatment with antibacterials are at an increased risk when using this medicine. Such patients are more likely to develop mild
diarrhea to the fatal inflammation of the digestive tract. If there is an existence of Clostridium difficile-associated diarrhea, the ongoing
antibiotic treatment should be discontinued. Appropriate fluid and electrolyte management, supplementation with protein, antibiotic treatment of Clostridium difficile, and surgical evaluation should be employed as required.
Microbial Overgrowth
Patients on treatment with antibacterials are at an increased risk to develop superinfection with fungal or bacterial microbes. If there is a possibility of fungal or bacterial superinfections, then discontinue or interrupt the treatment with Cefuroxime AXetil.
Development of Drug Resistance
Patients who are on treatment with
antibiotics in the absence of a bacterial infection are at an increased risk to develop drug resistance. Antibiotics including Cefuroxime AXetil should only be taken in the presence of confirmed bacterial infection.
Phenylketonuric Patients
Such patients should take Cefuroxime AXetil with care because it contains aspartame.
Interference with Glucose Test
Patients on treatment with Cefuroxime AXetil are at an increased risk for the false-positive result for glucose in the urine and a false-negative result for blood glucose. It is recommended to follow other alternative methods of testing such as glucose oxidase and hexokinase methods to determine blood glucose levels in patients receiving Cefuroxime AXetil.
Jarisch-Herxheimer Reaction
Patients while treatment with Cefuroxime AXetil is at an increased risk to develop the reaction caused by harmful products released into the body after killing of microbes.
Interference with Diagnostic Tests
Use of Cefuroxime AXetil may interfere with cross-matching compatibility of blood in between donor and recipient. It is recommended to follow other alternative methods of testing such as glucose oxidase and hexokinase methods to determine blood glucose levels in patients receiving Cefuroxime AXetil.